AZ awaits news of new indications for Seroquel

Anglo-Swedish drug major AstraZeneca says that the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee will discuss  the safety and efficacy of the supplemental New Drug Applications for  Seroquel XR (quetiapine fumarate), in the treatment of major depressive  disorder and generalised anxiety disorder, respectively, at its April  meeting.

Seroquel XR was approved in the USA in 2007 for the acute and  maintenance treatment of schizophrenia in adult patients and, in October  2008, for the acute treatment of the depressive episodes associated with  bipolar disorder, the manic and mixed episodes associated with bipolar I  disorder, as well as maintenance therapy for bipolar I disorder as  adjunctive therapy to lithium or divalproex.